Professor Pamela McCombe
Professor

Pamela McCombe

Email: 
Phone: 
+61 7 334 66017

Background

Neurologist

Dr McCombe graduated in Medicine from UQ and completed a Science degree for medical students. She then trained as a neurologist in Sydney, at Prince Henry and Prince of Wales Hospitals. She obtained a PhD from the University of Sydney. She obtained experience in Neurophysiology in Cleveland and then returned to UQ as a post-doctoral fellow. She worked for some years as a research fellow in Neuroimmunology and was an NHMRc SRF. Later she resumed clinical practice as a neurologist, and contimued her research as an NHMRC Practitioner Fellow. She is currentlyProfessor and Head of the Royal Brisbane Clinical school in the School of Medicine and Co-head of the Brain and Mental Health Theme at the UQ Centre for Clinical Research.

Availability

Professor Pamela McCombe is:
Available for supervision

Fields of research

Clinical sciences Immunology Statistics

Qualifications

  • Bachelor of Science, The University of Queensland
  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University of Sydney
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians

Research interests

  • Biomarkers and heterogeneity in ALS

    One of the challenges of ALS is understanding disease heterogeneity. Our work studies the variability of patients by detailed clinical, laboratory and genetic studies, and by identifying biomarkers that are associated with disease. We use a range of techniques including neurophysiology, MRI, metabolic studies, genetic studies, immune markers and biochemical studies including proteomics. We are using this information to analyse whether patients can be assigned into subgroups and to correlated with survival.

  • Inflammatory neuropathy studies

    This is an ongoing study of the immunological basis and genetic basis of acute and chronic inflammatory neuropathy

  • Pregnancy and MS

    This study is exploring the short and long term effects of pregnancy in multiple sclerosis. This includes the clinical effects of pregnancy and the effects on gene expression and methylation

  • Immunology of stroke

    This study involves documenting the immune responses after human stroke and determining the significance of these responses.

  • Neuromuscular disease

    This work is based at the Neuromuscular clinic at Royal Brisbane and Women's Hospital, and involves correlation of genotype and phenotype of inherited neuromuscular disease

Search Professor Pamela McCombe’s works on UQ eSpace

450 works between 1975 and 2025
All (450) Journal Article (306) Book Chapter (4) Conference Publication (137) Book (1) Other Outputs (1) Edited Outputs (1)

241 - 260 of 450 works

2016

Journal Article

A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma

McCombe, Pamela, Raj, Meenakshi, Henderson, Robert and Blum, Stefan (2016). A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma. Journal of Clinical Neuromuscular Disease, 17 (3), 129-134. doi: 10.1097/CND.0000000000000101

A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma

2016

Conference Publication

Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study

McCombe, P. A., Hartung, H-P, Havrdova, E., Selmaj, K. W., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD.

Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study

2016

Conference Publication

Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.

McCombe, P., Achiron, A., Chambers, C., Fox, E. J., Otero, S., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD.

Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.

2016

Conference Publication

Pregnancy Outcomes in Alemtuzumab-Treated Patients with Rrms

Rog, David, Chambers, Christina, McCombe, Pamela, Otero, Susana, Hellwig, Kerstin, Margolin, David, Thangavelu, Karthinathan and Oh, Jiwon (2016). Pregnancy Outcomes in Alemtuzumab-Treated Patients with Rrms. Annual Meeting of the Association-of-British-Neurologists (ABN), Brighton, England, May 17-19, 2016. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2016-315106.155

Pregnancy Outcomes in Alemtuzumab-Treated Patients with Rrms

2016

Conference Publication

Pregnancy protects against long-term disability accrual in relapsing-remitting MS

Jokubaitis, V. G., Kalincik, T., Lorscheider, J., Spelman, T., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., Grammond, P., Pucci, E., Grand'Maison, F., Granella, F., Sola, P., Bergamaschi, R., Iuliano, G., Spitaleri, D., Hodgkinson, S., Olascoaga, J., Verheul, F., McCombe, P., Rozsa, C., Lechner-Scott, J., Terzi, M., Hughes, S., Saladino, M. -L., Lugaresi, A., Trojano, M. and Butzkueven, H. (2016). Pregnancy protects against long-term disability accrual in relapsing-remitting MS. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Pregnancy protects against long-term disability accrual in relapsing-remitting MS

2016

Conference Publication

Individual response to disease modifying therapies: a global observational cohort study

Kalincik, T., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Girard, M., Prat, A., Duquette, P., Grammond, P., Sola, P., Hupperts, R., Grand'Maison, F., Pucci, E., Boz, C., Alroughani, R., Van Pesch, V., Lechner-Scott, J., Terzi, M., Bergamaschi, R., Iuliano, G., Granella, F., Spitaleri, D., Shaygannejad, V., Oreja-Guevara, C., Slee, M. ... Butzkueven, H. (2016). Individual response to disease modifying therapies: a global observational cohort study. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Individual response to disease modifying therapies: a global observational cohort study

2016

Conference Publication

Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

Coles, A. J., Boyko, A. N., Cohen, J. A., De Seze, J., Fox, E. J., Havrdova, E., Hartung, H. -P., Inshasi, J. S., McCombe, P., Selmaj, K. W., Vermersch, P., Van Wijmeersch, B., Margolin, D. H., Thangavelu, K., Rodriguez, C. E. and Montalban, X. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

2016

Conference Publication

Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

Kalincik, T., Brown, J. W., Robertson, N., Willis, M., Scolding, N., Pearson, O., Ziemssen, T., Hutchinson, M., McGuigan, C., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Alroughani, R., Pucci, E., Sola, P., Hupperts, R., Lechner-Scott, J., Fernandez Bolanos, R., Terzi, M., Van Pesch, V., Rozsa, C. ... Coles, A. (2016). Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

2016

Conference Publication

Australian cladribine experience

Kalincik, T., Lizak, N., Jokubaitis, V., Butler, E., Lechner-Scott, J., Slee, M., McCombe, P., Shaw, C., Skibina, O., Vucic, S., Shuey, N., Barnett, M., Parratt, J., Butzkueven, H. and Hodgkinson, S. (2016). Australian cladribine experience. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Australian cladribine experience

2016

Conference Publication

Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)

Oreja-Guevara, C., Alroughani, R., Brassat, D., Boyko, A. N., McCombe, P., Steingo, B., Van Wijmeersch, B., Margolin, D. H., Thangavelu, K., Rodriguez, C. E. and Vermersch, P. (2016). Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up). 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)

2015

Journal Article

Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis

Devine, Matthew S., Ballard, Emma, O'Rourke, Peter, Kiernan, Matther C., Mccombe, Pamela A. and Henderson, Robert D. (2015). Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17 (3-4), 1-7. doi: 10.3109/21678421.2015.1125502

Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis

2015

Conference Publication

Defining secondary progressive multiple sclerosis

Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pam, Vucic, Steve, Barnett, Michael, Butzkueven, Helmut and Kalincik, Tomas (2015). Defining secondary progressive multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne Australia, Oct 29-30, 2015. LONDON: SAGE PUBLICATIONS LTD.

Defining secondary progressive multiple sclerosis

2015

Journal Article

Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis

Ngo, S. T., Steyn, F. J., Huang, L., Mantovani, S., Pfluger, C. M. M., Woodruff, T. M., O'Sullivan, J. D., Henderson, R. D. and McCombe, P. A. (2015). Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 357 (1-2), 22-27. doi: 10.1016/j.jns.2015.06.053

Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis

2015

Journal Article

Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome

Chan, Adeline, Yan, Jun, Csurhes, Peter, Greer, Judith and McCombe, Pamela (2015). Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome. Journal of Neuroimmunology, 286, 42-47. doi: 10.1016/j.jneuroim.2015.06.013

Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome

2015

Journal Article

When does ALS start? A novel SOD-1 p.Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms

Ioannides, Z. A., Henderson, R. D., Robertson, T., Davis, M. and McCombe, P. A. (2015). When does ALS start? A novel SOD-1 p.Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms. Journal of Neurology, Neurosurgery and Psychiatry, 87 (9), 1031-1032. doi: 10.1136/jnnp-2015-311582

When does ALS start? A novel SOD-1 p.Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms

2015

Conference Publication

Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

Stewart, T., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Prat, A., Lugaresi, A., Grammond, P., Grand'Maison, F., Sola, P., Hupperts, R., Petersen, T., Pucci, E., Bergamaschi, R., Boz, C., Oreja-Guevara, C., Lechner-Scott, J., Alroughani, R., Ramo, C., Van Pesch, V., Fernandez-Bolanos, R., Iuliano, G., Rio, M. E., Granella, F., Slee, M. ... Kalincik, T. (2015). Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

2015

Conference Publication

Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program

Achiron, A., Chambers, C., Fox, E. J., Mc Combe, P., Otero, S., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2015). Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program

2015

Conference Publication

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Jokubaitis, V. G., Spelman, T., Kalincik, T., Travaglini, D., Paolicelli, D., Duquette, P., Girard, M., Prat, A., Havrdova, E., Horakova, D., Izquierdo, G., Grammond, P., Pucci, E., Grand'Maison, F., Bergamaschi, R., Granella, F., Van Pesch, V., Hupperts, R., Iuliano, G., Spitaleri, D., Sola, P., Boz, C., Fernandez-Bolanos, R., Petersen, T., Verheul, F., Olascoaga, J., McCombe, P., Rozsa, C., Lechner-Scott, J. ... Trojano, M. (2015). 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

2015

Conference Publication

Defining secondary progressive multiple sclerosis

Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Prat, A., Lugaresi, A., Grand'Maison, F., Grammond, P., Hupperts, R., Alroughani, R., Sola, P., Boz, C., Terzi, M., Pucci, E., Lechner-Scott, J., Bergamaschi, R., Oreja-Guevara, C., Iuliano, G., Van Pesch, V., Bolanos, R. Fernandez, Granella, F., Rio, M. E., Ramo, C. ... Kalincik, T. (2015). Defining secondary progressive multiple sclerosis. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

Defining secondary progressive multiple sclerosis

2015

Journal Article

A new era in the treatment of multiple sclerosis

Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith M., Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., King, John, McCombe, Pamela A., Pollard, John D. and Willoughby, Ernest (2015). A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 203 (3), 139-141e.1. doi: 10.5694/mja14.01218

A new era in the treatment of multiple sclerosis

Current funding

  • 2024 - 2026
    Using a novel humanized mouse model to investigate how EBV infection at different ages potentiates development of CNS demyelinating disease
    United States Congressionally Directed Medical Research Programs - Multiple Sclerosis Research Program
    Open grant
  • 2023 - 2027
    How does Epstein-Barr virus infection lead to multiple sclerosis?
    NHMRC MRFF CTAI and EPCDRI Multiple Sclerosis
    Open grant
  • 2023 - 2026
    Target validation of acid-sensing ion channel inhibitors to stop disease progression and manage pain in MS
    National Multiple Sclerosis Society-US
    Open grant
  • 2020 - 2025
    Assessing the effects of cladribine on vaccine recall responses in multiple sclerosis.
    Merck Healthcare KGaA
    Open grant
  • 2020 - 2025
    A novel biomarker for ALS
    Cure for MND Foundation - Impact Grants
    Open grant

Past funding

  • 2023 - 2025
    Using a novel humanized mouse model to investigate how EBV infection at different ages potentiates development of CNS demyelinating disease
    National Multiple Sclerosis Society-US
    Open grant
  • 2023 - 2024
    An Australian Sporadic ALS transcriptome resource
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2025
    Investigating effects of Evobrutinib on immune and non-immune cells in microglia-enhanced brain organoids
    Merck Group T/A Ares Trading SA
    Open grant
  • 2022 - 2023
    Excitotoxins in the plasma of subjects with motor neurone disease
    Wesley Medical Research Ltd
    Open grant
  • 2022 - 2025
    Leveraging medical records to identify patients at risk of neurodegenerative disease
    Boosting Dementia Research Grants (PR4): European Union Joint Program on Neurodegenerative Disease Research (JPND) Call for Multinational Projects
    Open grant
  • 2022 - 2025
    A high-throughput system to identify ALS risk genes from genome-wide association studies
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2024
    Developing novel acid-sensing ion channel inhibitors as neuroprotective leads and diagnostic agents for multiple sclerosis
    Multiple Sclerosis Research Australia - Targeted Grant - Neurodegeneration
    Open grant
  • 2021 - 2022
    Targeting NAT1 to improve metabolism and slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND
    Motor Neurone Disease Research Institute of Australia Inc Linda Rynalski Bridge Funding Grant
    Open grant
  • 2021 - 2022
    Revisiting Excitotoxicity in ALS: how does this occur?
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2021 - 2022
    N-acetyltransferase 1, a modifier of disease outcome in patients with Motor Neurone Disease (MND).
    Metro North Hospital and Health Service
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2021
    Possible gut derived toxins in ALS: prevalence and effects on outcome
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the immunometabolic nature of motor neurone disease (MND): a study linking metabolism, inflammation, and clinical outcomes in MND patients
    Metro North Hospital and Health Service
    Open grant
  • 2020 - 2022
    Development of biomarkers for loss of fat free mass and disease progression in patients with Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2019 - 2020
    Immunogenetics of motor neurone disease - a pilot study
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2022
    Multiple Sclerosis: Pregnancy and Prognosis (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2019 - 2020
    Role of NLRP3 inflammasome activation in the prognosis of secondary progressive multiple sclerosis
    Metro North Hospital and Health Service
    Open grant
  • 2018 - 2021
    A novel ephrin receptor A4-Fc fusion protein for the treatment of motor neuron disease
    Cure for MND Foundation - Translational Research Grants
    Open grant
  • 2018 - 2019
    Novel biomarkers for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2021
    EATT for MND: Exposing mechanisms of impaired appetite regulation in MND
    Wesley Medical Research Ltd
    Open grant
  • 2018 - 2019
    Longitudinal assessment of behaviour and cognition in ALS through brief Online Carers' behavioural Questionnaire (OCQ)
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Investigating the proteome of MND brains
    Metro North Hospital and Health Service
    Open grant
  • 2018
    Ion Mobility Separation of Challenging Clinical Samples
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018 - 2020
    Use of mass spectrometry to identify circulating toxins in the people with ALS
    Wesley Merdical Research
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    Targeting neuromuscular stability in motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    Cell-free DNA and ALS; insight into disease mechanisms and progression
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2020
    Assessment of metabolic health in neurodegeneration: studies in motor neurone disease (MND)
    Wesley Medical Research Ltd
    Open grant
  • 2017
    Discovery of EAAT5 - a protein that may stop glutamate excitotoxicity in ALS
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2019
    Does genetic variation in genes controlling pro-inflammatory immune responses modulate outcomes of MIS416 treatment in patients with multiple sclerosis?
    Wesley Medical Research Ltd
    Open grant
  • 2017 - 2018
    Metabolic exploration in neurodegenerative disease (MEND): synergy between derangements in systemic and muscle metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    Development of triheptanoin as a treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    Metabolic and gut dynamics in MND: Identifying novel strategies to meet energy needs in patients
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016
    Using biomarkers to explore heterogeneity of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015
    A multicentre study of the impact of metabolic balance and dietary intake on the clinical parameters of disease progression
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015
    Blood biomarkers in ALS: Translation into clinical practice of pNfH and search for additional biomarkers using proteomics
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015 - 2020
    Determining the contribution of peripheral immune complement signalling in the progression of motor neuron disease
    NHMRC Project Grant
    Open grant
  • 2015
    Mass spectrometry to search for biomarkers in motor neurone disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2015 - 2016
    Therapeutic targeting of the NLRP3 inflammasome using a potent and orally active inhibitor in experimental MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014
    Innate immune complement signalling in peripheral immune cells during the progression of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Investigating the consequences of increased fat catabolism in motor neurone disease (MND)
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014
    Investigation of a new gene involved in Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2014
    Mitochondrial analysis suite
    UQ Major Equipment and Infrastructure
    Open grant
  • 2014
    Targeting EphA4 as a treatment for MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Whole exome sequencing of sporadic MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013 - 2016
    A model for understanding and treating amyotrophic lateral sclerosis using induced pluripotent stem cells (An IPSC model of ALS)
    Smart Futures Fund - QCAS Biotechnology Projects Fund
    Open grant
  • 2013 - 2014
    Biomarkers of disease progression in MND
    UQ Academic Title Holder Research Fund
    Open grant
  • 2013 - 2014
    Investigating the causes and consequences of growth hormone dysfunction in motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    T cells in stroke - part of the solution?
    Royal Brisbane and Women's Hospital
    Open grant
  • 2013
    Use of biomarkers to understand Amyotrophic Lateral Sclerosis
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    Using biomarkers to assess disease progression and understanding of MND
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012 - 2013
    Blood Biomarkers in Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012
    Genetic Factors that predispose to GBS and CIDP
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012
    MND - not a simple disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011 - 2012
    Role of maternofetal chimerism in transferring susceptibility to MS
    National Multiple Sclerosis Society-US
    Open grant
  • 2011
    Comprehensive assessment of MND patients as a means to studying progression and identifying disease subtypes
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011
    Immunogenetic studies of Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy
    Royal Brisbane and Women's Hospital
    Open grant
  • 2011
    Nature and timing of inflammation after acute ischaemic stroke
    Royal Brisbane and Women's Hospital
    Open grant
  • 2011 - 2013
    Nature and timing of inflammation after acute ischaemic stroke
    National Heart Foundation of Australia
    Open grant
  • 2011 - 2013
    NFKBIA mutations as a mechanism leading to constitutive activation of NF-kB in patients with primary progressive MS
    Multiple Sclerosis Research Australia
    Open grant
  • 2011 - 2013
    The role of the innate immune system during the progression of motor neuron disease; the search for new therapeutic targets
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2009
    Assessment of Disease Progression in Motor Neurone Disease
    Royal Brisbane & Women's Hospital Research Foundation
    Open grant
  • 2009 - 2012
    Development of a new method of motor unit number estimation for use in motor neurone disease
    NHMRC Project Grant
    Open grant
  • 2009 - 2010
    Identifying biomarkers for MND using flow cytometry.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2009 - 2011
    The effects of pregnancy and the post-partum period on T cells, antibodies, and gene expression in EAE
    Multiple Sclerosis Research Australia
    Open grant
  • 2008 - 2012
    Immune Response to stroke
    Wesley Merdical Research
    Open grant
  • 2006 - 2008
    Characterisation of peripheral immune response to ischaemic stroke
    Royal Brisbane Hospital
    Open grant
  • 2005 - 2006
    Start-up Grant
    Royal Brisbane & Women's Hospital Research Foundation
    Open grant
  • 2002 - 2004
    Motor Unit Analysis in Motor Neurone Disease
    Motor Neurone Disease Association Queensland Inc
    Open grant
  • 2000 - 2003
    Early pregnancy factor and experimental autoimmune encephalomyelitis
    National Multiple Sclerosis Society-US
    Open grant
  • 1999
    A study of T cell reactivity in patients with Guillain-Barre Syndrome and chronic inflammatory demyelinating polyneuropathy
    Royal Australasian College of Physicians
    Open grant
  • 1999 - 2001
    Correlation Between Ganglioside-Specific Immune Responses and Disease Prograssion in Multiple Sclerosis
    NHMRC Project Grant
    Open grant
  • 1999
    T Cells and cytokines in inflammatory neuropathy
    Mayne Bequest Fund
    Open grant
  • 1999 - 2000
    The use of early pregnancy factor as treatment for experimental autoimmune encephalomyelitis
    National Multiple Sclerosis Society of Australia
    Open grant
  • 1998
    Early Pregnancy Factor and Experimental Autoimmune Encephalomyelitis
    Mayne Bequest Fund
    Open grant
  • 1996 - 1998
    Studies of T cell reactivity to myelin antigens in multiple sclerosis
    NHMRC Project Grant
    Open grant
  • 1996 - 2000
    Studies of the mechanisms of relapse of experimental autoimmune encephalomyelitis
    NHMRC Project Grant - 5 Yr Extended with Fellow
    Open grant
  • 1995 - 1997
    Modulation of autoreactive T cell apoptosis in experimental autoimmune encephalomyelitis
    NHMRC Project Grant - Standard
    Open grant

Availability

Professor Pamela McCombe is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Professor Pamela McCombe's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au